DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Azacytidine is an investigational drug.
There have been 132 clinical trials for Azacytidine. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2019.
The most common disease conditions in clinical trials are Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, and Preleukemia. The leading clinical trial sponsors are National Cancer Institute (NCI), M.D. Anderson Cancer Center, and Celgene Corporation.
Recent Clinical Trials for Azacytidine
|Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting||National Cancer Institute (NCI)||Phase 2|
|Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting||M.D. Anderson Cancer Center||Phase 2|
|Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase Chronic Myelogenous Leukemia||National Cancer Institute (NCI)||Phase 2|